Filtered By:
Condition: Cholesterol
Therapy: Immunotherapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 16 results found since Jan 2013.

GSE233807 RNA N6-methyladenosine methyltransferase METTL3 drives NAFLD-HCC and is a therapeutic target for boosting immunotherapy m6A-seq
Series Type : Methylation profiling by high throughput sequencingOrganism : Homo sapiensNon-alcoholic fatty liver disease (NAFLD) is an emerging risk factor of hepatocellular carcinoma (HCC). However, the mechanism and target therapy on NAFLD-HCC are still unclear. Here, we identify that the N6-methyladenosine (m6A) methyltransferase METTL3 promotes NAFLD-HCC. Hepatocyte-specific Mettl3 knockin exacerbated NAFLD-HCC formation while Mettl3 knockout exerted an opposite effect in mice. Single-cell RNA-seq revealed that METTL3 suppressed antitumor immune response by reducing infiltration of Gzmb+ and IFN- γ+ CD8+ T-cell, ther...
Source: GEO: Gene Expression Omnibus - August 23, 2023 Category: Genetics & Stem Cells Tags: Methylation profiling by high throughput sequencing Homo sapiens Source Type: research

GSE233806 RNA N6-methyladenosine methyltransferase METTL3 drives NAFLD-HCC and is a therapeutic target for boosting immunotherapy RNA-Seq
Series Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensNon-alcoholic fatty liver disease (NAFLD) is an emerging risk factor of hepatocellular carcinoma (HCC). However, the mechanism and target therapy on NAFLD-HCC are still unclear. Here, we identify that the N6-methyladenosine (m6A) methyltransferase METTL3 promotes NAFLD-HCC. Hepatocyte-specific Mettl3 knockin exacerbated NAFLD-HCC formation while Mettl3 knockout exerted an opposite effect in mice. Single-cell RNA-seq revealed that METTL3 suppressed antitumor immune response by reducing infiltration of Gzmb+ and IFN- γ+ CD8+ T-cell, there...
Source: GEO: Gene Expression Omnibus - August 23, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Lipoprotein(a) lowering and cardiovascular risk reduction by PCSK9 inhibitors
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition augments recirculation of the low-density lipoprotein (LDL) receptor to the hepatocyte surface [1], thereby lowering atherogenic particles through accelerated clearance of circulating LDL cholesterol (LDL-C). This observation led to several strategies to inhibit PCSK9, including monoclonal antibodies (evolocumab and alirocumab), small-molecule inhibitors specific to PCSK9, small interfering RNA (siRNA) molecules (inclisiran), antisense oligonucleotides, immunotherapy with a PCSK9 peptide vaccine, and CRISPR/Cas9 editing of PCSK9.
Source: Atherosclerosis - October 21, 2022 Category: Cardiology Authors: Maya S. Safarova, Iftikhar J. Kullo Tags: Editorial Source Type: research

PCSK9 as a new player in cancer: New opportunity or red herring?
Curr Med Chem. 2021 Nov 15. doi: 10.2174/0929867328666211115122324. Online ahead of print.ABSTRACTInitially described as a factor involved in liver regeneration and neuronal differentiation, proprotein convertase subtilisin/kexin type 9 (PCSK9) has become one of the key regulators of low-density lipoprotein cholesterol. Besides that, a number of studies have suggested PCSK9 may play a role in cancer biology. This is particularly true for gastroenteric (gastric and liver cancers) and lung cancers, where higher PCSK9 levels were associated with the increased ability of the tumor to develop and give metastasis as well as with...
Source: Current Medicinal Chemistry - November 16, 2021 Category: Chemistry Authors: Aldo Bonaventura Alessandra Vecchi é Massimiliano Ruscica Francesco Grossi Francesco Dentali Source Type: research

The multifaceted biology of PCSK9
This article reviews the discovery of PCSK9, its structure-function characteristics, and its presently known and proposed novel biological functions. The major critical function of PCSK9 deduced from human and mouse studies, as well as cellular and structural analyses, is its role in increasing the levels of circulating LDL-cholesterol (LDLc), via its ability to enhance the sorting and escort of the cell surface LDL receptor (LDLR) to lysosomes. This implicates the binding of the catalytic domain of PCSK9 to the EGF-A domain of the LDLR. This also requires the presence of the C-terminal Cys/His-rich domain (CHRD), its bind...
Source: Endocrine Reviews - October 9, 2021 Category: Endocrinology Authors: Nabil G Seidah Annik Prat Source Type: research

A novel tumour suppressor lncRNA F630028O10Rik inhibits lung cancer angiogenesis by regulating miR-223-3p.
In this study, we carried out RNA sequencing (RNA-Seq) of tumour tissues isolated from LLC tumour-bearing mice treated with either Plasmodium yoelli (Py)-infected red blood cells or uninfected red blood cells. We found that F630028O10Rik (abbreviated as F63) is a novel lncRNA that was significantly up-regulated in tumours isolated from mice treated with Py-infected red blood cells compared to the control. By using gene silencing technique, F63 was found to inhibit both tumour Vascular Endothelial Growth Factor A (VEGFA) secretion and endothelial cells clone formation, migration, invasion and tube formation. Injection of ch...
Source: J Cell Mol Med - February 12, 2020 Category: Molecular Biology Authors: Qin L, Zhong M, Adah D, Qin L, Chen X, Ma C, Fu Q, Zhu X, Li Z, Wang N, Chen Y Tags: J Cell Mol Med Source Type: research

Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing
In conclusion, the method of NK cell transfection described in our present study is highly efficient, does not require expensive dedicated structures necessary for viral transduction and avoids possible risks associated with the use of viral vectors. Importantly, it may be applied to NK cells or NK-92 cell line, greatly improving their anti-tumor activity and providing a new NK cell-based platform for new protocols of adoptive immuno-therapy of cancer. Ethics Statement The Ethical Committee of IRCCS Bambino Gesù Pediatric Hospital approved the study (825/2014). Author Contributions TI designed and performed res...
Source: Frontiers in Immunology - April 29, 2019 Category: Allergy & Immunology Source Type: research